文献速递传染病防控与疫情报告妇幼与学校卫生

湖北省妇幼保健院2023至2024年14岁及以下急性呼吸道感染住院儿童鼻病毒临床流行病学特征分析

[Analysis of the clinical epidemiological characteristics of rhinovirus in hospitalized children aged 14 years and younger with acute respiratory tract infection in a maternal and child health hospital in Hubei Province from 2023 to 2024].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2025-01-01

回顾性纳入2023年1月至2024年12月湖北省妇幼保健院因急性呼吸道感染住院且行靶向高通量测序的儿童32 016例,鼻病毒阳性率为21.28%(6 814/32 016),以RV-A为主,3~<6岁组阳性率最高;混合感染是鼻病毒感染后发生肺炎的主要危险因素(OR=1.721,95%CI=1.581~1.871,P<0.001)。

要点

  • RV阳性率21.28%(6 814/32 016),3~<6岁组最高为24.66%(2 663/10 801)。
  • RV-A检出最多,占58.95%(4 017/6 814);混合检出率51.91%(3 537/6 814),以肺炎支原体最常见。
  • 混合检出组肺炎发生率68.59%(2 426/3 537)高于单检出组51.33%(1 682/3 277),差异有统计学意义。

核心结论

  • 本研究中RV流行季节集中于春秋季,流行型别以RV-A为主,3~<6岁年龄组RV阳性率最高。
  • RV易合并其他呼吸道病原感染,其中与MP混合感染最多见,混合感染可能导致病情加重,需在临床上引起重视。

研究设计与样本

  • 回顾性、观察性研究,纳入2023年1月至2024年12月在湖北省妇幼保健院因ARI住院且进行了靶向高通量测序检测的患儿共32 016例。

主要发现

  • RV阳性率为21.28%(6 814/32 016)。
  • <6月龄、6月龄~<1岁、1~<3岁、3~<6岁、6~≤14岁年龄组阳性率分别为20.38%(459/2 252)、23.14%(506/2 187)、23.76%(1 462/6 153)、24.66%(2 663/10 801)、16.23%(1 724/10 623),差异有统计学意义(χ2=263.403,P<0.05)。
  • RV检出率在2023年2月和5月出现两个高峰;2024年在3—6月和10—11月保持在较高水平。
  • RV三型中RV-A检出最多,检出率为58.95%(4 017/6 814);RV与其他病原混合检出率为51.91%(3 537/6 814),以MP为主,其次为PIV、RSV、ADV、HMPV和甲型流感病毒H3N2。
  • 6 814例RV阳性患儿中肺炎占60.29%;混合检出组肺炎发生率68.59%(2 426/3 537)、重症肺炎发生率2.71%(96/3 537),单检出组肺炎发生率51.33%(1 682/3 277)、重症肺炎发生率1.83%(60/3 277),混合检出组均高于单检出组,差异有统计学意义(χ2=211.702,P<0.05;χ2=5.932,P<0.05)。

临床怎么用

  • 原文结论指出混合感染可能导致病情加重,需在临床上引起重视。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To explore the clinical epidemiological characteristics of rhinovirus (RV) infection in children hospitalized due to acute respiratory infection (ARI) in the Maternal and Child Health Hospital of Hubei Province. A retrospective, observational study was conducted, including 32 016 children hospitalized with acute respiratory infections (ARI) who underwent targeted high-throughput sequencing (tNGS) at the Maternal and Child Health Hospital of Hubei Province from January 2023 to December 2024. Clinical data were collected to analyze the epidemiological characteristics and related clinical manifestations of RV. Comparisons between groups were performed using the χ2 test, and multivariate logistic regression analysis was applied to identify risk factors associated with RV-related pneumonia. The results showed that the positive rate of RV was 21.28% (6 814/32 016). The positive rates in the age groups of <6 months, 6 months to <1 year, 1 to <3 years, 3 to <6 years, and 6 to ≤14 years were 20.38% (459/2 252), 23.14% (506/2 187), 23.76% (1 462/6 153), 24.66% (2 663/10 801), and 16.23% (1 724/10 623), respectively, with statistically significant differences (χ2=263.403, P<0.05). The detection rate of RV reached two peaks in February and May 2023; in 2024, it remained at a relatively high level from March to June and from October to November. Among the three types of RV, RV-A was the most frequently detected, with a detection rate of 58.95% (4 017/6 814). The mixed detection rate of RV with other pathogens was 51.91% (3 537/6 814). The pathogens mixed with RV were mainly Mycoplasma pneumoniae (MP), followed by parainfluenza virus (PIV), respiratory syncytial virus (RSV), adenovirus (ADV), human metapneumovirus (HMPV), and influenza A virus H3N2. Among the 6 814 RV-positive children included in this study, pneumonia (60.29%) was the most common clinical manifestation following RV infection.The pneumonia incidence rate in the RV mixed detection group was 68.59% (2 426/3 537), and the incidence rate of severe pneumonia was 2.71% (96/3 537). The pneumonia incidence rate in the RV single detection group was 51.33% (1 682/3 277), and the incidence rate of severe pneumonia was 1.83% (60/3 277). The pneumonia incidence rate and the incidence rate of severe pneumonia in the mixed infection group were both higher than those in the single detection group, with statistically significant differences (χ2=211.702, P<0.05; χ2=5.932, P<0.05). Multivariate logistic regression analysis showed that co-infection was the major risk factor for pneumonia in children with RV infection [OR=1.721, 95% confidence interval(CI)=1.581-1.871, P<0.001]. In conclusion, the epidemic season of RV was concentrated in spring and autumn, and the predominant type was RV-A in this study. The age group of 3 to <6 years had the highest positive rate of RV. RV is prone to co-infection with other respiratory pathogens, with MP being the most common. Mixed infection may lead to aggravated conditions and should be given attention in clinical practice. 本研究探讨湖北省妇幼保健院因急性呼吸道感染(acute respiratory infection,ARI)住院的患儿中鼻病毒(rhinovirus,RV)感染的临床流行病学特征。采用回顾性、观察性研究,纳入2023年1月至2024年12月在湖北省妇幼保健院因ARI住院且进行了靶向高通量测序检测的患儿的临床资料共32 016例,收集患儿临床资料,以分析RV的流行特征及相关临床表现,组间比较采用χ2检验,采用多因素logistic回归分析总结RV肺炎发生相关的危险因素。结果显示,RV阳性率为21.28%(6 814/32 016)。<6月龄、6月龄~<1岁、1~<3岁、3~<6岁、6~≤14岁年龄组的阳性率分别为20.38%(459/2 252)、23.14%(506/2 187)、23.76%(1 462/6 153)、24.66%(2 663/10 801)、16.23%(1 724/10 623),差异有统计学意义(χ2=263.403,P<0.05)。RV检出率在2023年2月和5月出现两个高峰;在2024年则在3—6月和10—11月保持在较高水平。RV三型中RV-A检出最多,检出率为58.95%(4 017/6 814)。RV与其他病原的混合检出率为51.91%(3 537/6 814);与RV混合检出的病原体以肺炎支原体(Mycoplasma pneumoniae,MP)为主,其次为副流感病毒(parainfluenza virus,PIV)、呼吸道合胞病毒(respiratory syncytial virus,RSV)、腺病毒(adenovirus,ADV)、偏肺病毒(human metapneumovirus,HMPV)和甲型流感病毒H3N2。在本研究纳入的6 814例RV阳性患儿中,肺炎(60.29%)是RV感染后最常见的临床表现,RV混合检出组肺炎发生率为68.59%(2 426/3 537),重症肺炎发生率为2.71%(96/3 537),RV单检出组的肺炎发生率为51.33%(1 682/3 277),重症肺炎发生率为1.83%(60/3 277),混合感染组的肺炎发生率与重症肺炎发生率均高于单检出组,差异有统计学意义(χ2=211.702,P<0.05;χ2=5.932,P<0.05)。多因素logistic回归分析显示,混合感染是儿童感染RV后发生肺炎的主要危险因素[OR=1.721,95%置信区间(CI)=1.581~1.871,P<0.001]。综上,本研究中RV的流行季节集中于春秋季,流行型别以RV-A为主,3~<6岁年龄组RV阳性率最高。RV易合并其他呼吸道病原感染,其中与MP混合感染最多见,混合感染可能导致病情加重,需在临床上引起重视。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang AB, Wang AC, Liang A, et al. [Analysis of the clinical epidemiological characteristics of rhinovirus in hospitalized children aged 14 years and younger with acute respiratory tract infection in a maternal and child health hospital in Hubei Province from 2023 to 2024]. Zhonghua Yu Fang Yi Xue Za Zhi. 2025. PMID: 41429551. doi:10.3760/cma.j.cn112150-20250905-00860

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。